Objective: To investigate the clinic value of transarterial infusion chemotherapy of gemcitabine for post radical excision in patients with cancer of pancreatic head. Methods: 66 patients with cancer of pancreatic head were divided to the control group (32 patients) and the therapeutic group (34 patients). The control group received traditional vein chemotherapy of gemcitabine while the therapeutic group received transarterial infusion chemotherapy of gemcitabine. The incidence rate of adverse event, the liver metastasis rate, local recurrence rate and survival time were compared between the two groups after operation. Results: 1) according to the stage standard of WHO, the incidence rate of the decreace of blood cell in the control group is significantly higher than the therapeutic group（P<0.05）; 2) the liver metastasis rate, local recurrence rate and survival time in 1 year and 3 years are individually 17%, 42% and 44%, 11% in the therapeutic group while in the control group the liver metastasis rate, local recurrence rate and survival time in 1 year and 3 years are individually 73%, 68% and 16%, 3%. There is significantly statistical difference between the two groups（P<0.05） .Conclusion: transarterial infusion chemotherapy of gemcitabine for post radical excision in patients with cancer of pancreatic head can improve the survival quality of patients, reduce the recurrence rate and prolong the survival period of patients.